Dolutegravir and Ertugliflozin Interaction

Drug interaction information between Dolutegravir and Ertugliflozin.

Dolutegravir and Ertugliflozin have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Dolutegravir and Ertugliflozin. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Dolutegravir

Integrase Strand Transfer Inhibitor

Drug B

Ertugliflozin

SGLT2 Inhibitor

How They Interact

Dolutegravir blocks the kidneys from removing metformin from the body, which causes metformin levels to rise and increases the risk of side effects.

FDA Label Information

Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risks of concomitant use.

Ertugliflozin Also Interacts With

View all Ertugliflozin interactions →

Frequently Asked Questions

What SPL severity band is on file for Dolutegravir + Ertugliflozin?

Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Dolutegravir has 28 labeled pairs on file vs Ertugliflozin's 8. In the moderate band specifically: Dolutegravir has 6 (also Empagliflozin, Empagliflozin/Linagliptin, Linagliptin, Metformin/Empagliflozin); Ertugliflozin has 6 (also Metformin, Topiramate, Ranolazine, Cimetidine).

What mechanism field is on file for Dolutegravir and Ertugliflozin?

Dolutegravir blocks the kidneys from removing metformin from the body, which causes metformin levels to rise and increases the risk of side effects.

Dolutegravir carries more major-labeled pairs than Ertugliflozin

SPL source-record counts only. This page's band is moderate · classes on file: Dolutegravir (Integrase Strand Transfer Inhibitor); Ertugliflozin (SGLT2 Inhibitor).

Dolutegravir has 1 major-labeled pair vs Ertugliflozin's 0. This page itself is in the moderate band, not the major band.

Dolutegravir

1 major · 6 moderate · 21 minor · 28 total

Ertugliflozin

0 major · 6 moderate · 2 minor · 8 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.